RATIONALE: Calmodulin (CaM) mutations are associated with an autosomal dominant syndrome of ventricular arrhythmia and sudden death that can present with divergent clinical features of catecholaminergic polymorphic ventricular tachycardia (CPVT) or long QT syndrome (LQTS). CaM binds to and inhibits ryanodine receptor (RyR2) Ca release channels in the heart, but whether arrhythmogenic CaM mutants alter RyR2 function is not known. OBJECTIVE: To gain mechanistic insight into how human CaM mutations affect RyR2 Ca channels. METHODS AND RESULTS: We studied recombinant CaM mutants associated with CPVT (N54I and N98S) or LQTS (D96V, D130G, and F142L). As a group, all LQTS-associated CaM mutants (LQTS-CaMs) exhibited reduced Ca affinity, whereas CPVT-associated CaM mutants (CPVT-CaMs) had either normal or modestly lower Ca affinity. In permeabilized ventricular myocytes, CPVT-CaMs at a physiological intracellular concentration (100 nmol/L) promoted significantly higher spontaneous Ca wave and spark activity, a typical cellular phenotype of CPVT. Compared with wild-type CaM, CPVT-CaMs caused greater RyR2 single-channel open probability and showed enhanced binding affinity to RyR2. Even a 1:8 mixture of CPVT-CaM:wild-type-CaM activated Ca waves, demonstrating functional dominance. In contrast, LQTS-CaMs did not promote Ca waves and exhibited either normal regulation of RyR2 single channels (D96V) or lower RyR2-binding affinity (D130G and F142L). None of the CaM mutants altered Ca/CaM binding to CaM-kinase II. CONCLUSIONS: A small proportion of CPVT-CaM is sufficient to evoke arrhythmogenic Ca disturbances, whereas LQTS-CaMs do not. Our findings explain the clinical presentation and autosomal dominant inheritance of CPVT-CaM mutations and suggest that RyR2 interactions are unlikely to explain arrhythmogenicity of LQTS-CaM mutations.
RATIONALE: Calmodulin (CaM) mutations are associated with an autosomal dominant syndrome of ventricular arrhythmia and sudden death that can present with divergent clinical features of catecholaminergic polymorphic ventricular tachycardia (CPVT) or long QT syndrome (LQTS). CaM binds to and inhibits ryanodine receptor (RyR2) Ca release channels in the heart, but whether arrhythmogenic CaM mutants alter RyR2 function is not known. OBJECTIVE: To gain mechanistic insight into how humanCaM mutations affect RyR2 Ca channels. METHODS AND RESULTS: We studied recombinant CaM mutants associated with CPVT (N54I and N98S) or LQTS (D96V, D130G, and F142L). As a group, all LQTS-associated CaM mutants (LQTS-CaMs) exhibited reduced Ca affinity, whereas CPVT-associated CaM mutants (CPVT-CaMs) had either normal or modestly lower Ca affinity. In permeabilized ventricular myocytes, CPVT-CaMs at a physiological intracellular concentration (100 nmol/L) promoted significantly higher spontaneous Ca wave and spark activity, a typical cellular phenotype of CPVT. Compared with wild-type CaM, CPVT-CaMs caused greater RyR2 single-channel open probability and showed enhanced binding affinity to RyR2. Even a 1:8 mixture of CPVT-CaM:wild-type-CaM activated Ca waves, demonstrating functional dominance. In contrast, LQTS-CaMs did not promote Ca waves and exhibited either normal regulation of RyR2 single channels (D96V) or lower RyR2-binding affinity (D130G and F142L). None of the CaM mutants altered Ca/CaM binding to CaM-kinase II. CONCLUSIONS: A small proportion of CPVT-CaM is sufficient to evoke arrhythmogenic Ca disturbances, whereas LQTS-CaMs do not. Our findings explain the clinical presentation and autosomal dominant inheritance of CPVT-CaM mutations and suggest that RyR2 interactions are unlikely to explain arrhythmogenicity of LQTS-CaM mutations.
Authors: Tao Guo; Bradley R Fruen; Florentin R Nitu; Trinh D Nguyen; Yi Yang; Razvan L Cornea; Donald M Bers Journal: Biophys J Date: 2011-11-01 Impact factor: 4.033
Authors: Christian van der Werf; Prince J Kannankeril; Frederic Sacher; Andrew D Krahn; Sami Viskin; Antoine Leenhardt; Wataru Shimizu; Naokata Sumitomo; Frank A Fish; Zahurul A Bhuiyan; Albert R Willems; Maurits J van der Veen; Hiroshi Watanabe; Julien Laborderie; Michel Haïssaguerre; Björn C Knollmann; Arthur A M Wilde Journal: J Am Coll Cardiol Date: 2011-05-31 Impact factor: 24.094
Authors: Qiang Zhou; Jianmin Xiao; Dawei Jiang; Ruiwu Wang; Kannan Vembaiyan; Aixia Wang; Chris D Smith; Cuihong Xie; Wenqian Chen; Jingqun Zhang; Xixi Tian; Peter P Jones; Xiaowei Zhong; Ang Guo; Haiyan Chen; Lin Zhang; Weizhong Zhu; Dongmei Yang; Xiaodong Li; Ju Chen; Anne M Gillis; Henry J Duff; Heping Cheng; Arthur M Feldman; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen Journal: Nat Med Date: 2011-07-10 Impact factor: 53.440
Authors: Lia Crotti; Carla Spazzolini; David J Tester; Alice Ghidoni; Alban-Elouen Baruteau; Britt-Maria Beckmann; Elijah R Behr; Jeffrey S Bennett; Connie R Bezzina; Zahurul A Bhuiyan; Alpay Celiker; Marina Cerrone; Federica Dagradi; Gaetano M De Ferrari; Susan P Etheridge; Meena Fatah; Pablo Garcia-Pavia; Saleh Al-Ghamdi; Robert M Hamilton; Zuhair N Al-Hassnan; Minoru Horie; Juan Jimenez-Jaimez; Ronald J Kanter; Juan P Kaski; Maria-Christina Kotta; Najim Lahrouchi; Naomasa Makita; Gabrielle Norrish; Hans H Odland; Seiko Ohno; John Papagiannis; Gianfranco Parati; Nicole Sekarski; Kristian Tveten; Matteo Vatta; Gregory Webster; Arthur A M Wilde; Julianne Wojciak; Alfred L George; Michael J Ackerman; Peter J Schwartz Journal: Eur Heart J Date: 2019-09-14 Impact factor: 29.983
Authors: Kafa Walweel; Nieves Gomez-Hurtado; Robyn T Rebbeck; Ye Wint Oo; Nicole A Beard; Peter Molenaar; Cris Dos Remedios; Dirk F van Helden; Razvan L Cornea; Björn C Knollmann; Derek R Laver Journal: J Mol Cell Cardiol Date: 2019-03-27 Impact factor: 5.000
Authors: Kafa Walweel; Nieves Gomez-Hurtado; Ye Wint Oo; Nicole A Beard; Cris Dos Remedios; Christopher N Johnson; Walter J Chazin; Dirk F van Helden; Björn C Knollmann; Derek R Laver Journal: J Am Coll Cardiol Date: 2017-07-04 Impact factor: 24.094
Authors: Ye Win Oo; Nieves Gomez-Hurtado; Kafa Walweel; Dirk F van Helden; Mohammad S Imtiaz; Bjorn C Knollmann; Derek R Laver Journal: Mol Pharmacol Date: 2015-04-28 Impact factor: 4.436
Authors: Manu Ben-Johny; Ivy E Dick; Lingjie Sang; Worawan B Limpitikul; Po Wei Kang; Jacqueline Niu; Rahul Banerjee; Wanjun Yang; Jennifer S Babich; John B Issa; Shin Rong Lee; Ho Namkung; Jiangyu Li; Manning Zhang; Philemon S Yang; Hojjat Bazzazi; Paul J Adams; Rosy Joshi-Mukherjee; Daniel N Yue; David T Yue Journal: Curr Mol Pharmacol Date: 2015 Impact factor: 3.339
Authors: Worawan B Limpitikul; Ivy E Dick; Rosy Joshi-Mukherjee; Michael T Overgaard; Alfred L George; David T Yue Journal: J Mol Cell Cardiol Date: 2014-05-08 Impact factor: 5.000